8. Grifols SA ( GRFS) Company Profile: Grifols makes plasma derivatives, IV therapy, enteral nutrition, diagnostic systems and medical materials. Paulson's Investment: The hedge fund bought 14 million shares of Grifols during the second quarter, ending with a market value of $107 million as of June 30. Share Price Performance: Grifols is another ugly stock chart for Paulson as well as fellow hedge-fund investor Steven Cohen. Shares are down nearly 6% since the stock's debut in early June. After notching a high of $8.50 in late July, the stock has plunged as low as $6.33 earlier this month.